MARKET

VRNA

VRNA

Verona Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.88
-0.39
-4.21%
After Hours: 8.66 -0.22 -2.48% 17:09 03/03 EST
OPEN
9.24
PREV CLOSE
9.27
HIGH
9.27
LOW
8.66
VOLUME
177.87K
TURNOVER
--
52 WEEK HIGH
15.71
52 WEEK LOW
2.010
MARKET CAP
460.15M
P/E (TTM)
-2.6012
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Lisa Deschamps Joins Verona Pharma as Non-Executive Director
LONDON and RALEIGH, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces, effective March 1, 2021, Ms. Lisa Deschamps has joined t...
GlobeNewswire · 1d ago
The impact of COVID-19 on Drugs for Chronic Cough Market Size Estimation, Industry Share, Business Analysis, Growth Opportunities And Important Aspects By 2026
Mar 02, 2021 (The Expresswire) -- The report provides revenue of the globalDrugs for Chronic Cough Market for the period 2016 and 2026, considering 2020 as...
The Express Wire · 1d ago
Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference
LONDON and RALEIGH, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and Presi...
GlobeNewswire · 2d ago
Verona Pharma Plc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 25, 2021 / Verona Pharma Plc (NASDAQ:VRNA) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25, 2021 at 2:00 PM Eastern Time.
ACCESSWIRE · 6d ago
10-K: VERONA PHARMA PLC
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 6d ago
8-K: Verona Pharma plc
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 6d ago
Verona Pharma EPS beats by $0.30
Verona Pharma (VRNA): Q4 GAAP EPS of -$0.05 beats by $0.30.Cash and cash equivalents of $188M.Press Release
Seekingalpha · 6d ago
Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Positive Phase 2 results with pMDI ensifentrine in COPD
GlobeNewswire · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VRNA. Analyze the recent business situations of Verona Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VRNA stock price target is 19.20 with a high estimate of 25.00 and a low estimate of 17.00.
EPS
Institutional Holdings
Institutions: 44
Institutional Holdings: 37.61M
% Owned: 72.58%
Shares Outstanding: 51.82M
TypeInstitutionsShares
Increased
7
1.13M
New
13
1.83M
Decreased
4
307.47K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Non-Executive Chairman
David Ebsworth
President/Chief Executive Officer
David Zaccardelli
Chief Financial Officer
Mark Hahn
Vice President/Director of Investor Relations
David Moskowitz
Vice President - Research & Development
Tara Rheault
Secretary
Ben Harber
Non-Executive Director
Kenneth Cunningham
Non-Executive Director
Lisa Deschamps
Non-Executive Director
Vikas Sinha
Non-Executive Director
Anders Ullman
Non-Executive Independent Director
Martin Edwards
  • Dividends
  • Splits
  • Insider Activity
No Data
About VRNA
Verona Pharma plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. The Company is developing ensifentrine, the treatment for respiratory disease. Ensifentrine is an inhaled therapy that acts as both a bronchodilator and an anti-inflammatory agent in one compound. In addition to nebulized ensifentrine, the Company has developed dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI) formulations of ensifentrine for less severe patients. The Company’s subsidiaries include Verona Pharma Inc. and Rhinopharma Limited.

Webull offers kinds of Verona Pharma PLC - ADR stock information, including NASDAQ:VRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VRNA stock methods without spending real money on the virtual paper trading platform.